Valneva joins the phase 3 Covid-19 vaccine club
Meanwhile, Ocugen hopes that Covaxin's India data will be enough for US approval.
Biotech venture financing starts the year with a bang
With a record $7.1bn raised in the first quarter the cash available to private drug developers shows no signs of drying up.
J&J’s Covid-19 vaccine set to become third to US
FDA briefing documents show intriguing findings on asymptomatic prevention, though these are based on small numbers.
J&J pause adds to adenovirus vaccine doubts
Details are scant about the “unexplained illness” seen with Johnson & Johnson’s Covid-19 vaccine, but the news puts another dent in public confidence.
The next triggers in Covid-19 vaccine development
Pfizer/Biontech’s preprint might prove academic as investors look to pivotal study designs and readouts.
